Literature DB >> 10898678

Bactericidal activity of gentamicin against Enterococcus faecalis in vitro and in vivo.

A Lefort1, M Arthur, L Garry, C Carbon, P Courvalin, B Fantin.   

Abstract

The activity of gentamicin at various concentrations against two strains of Enterococcus faecalis was investigated in vitro and in a rabbit model of aortic endocarditis. In vitro, gentamicin at 0.5 to 4 times the MIC failed to reduce the number of bacteria at 24 h. Rabbit or human serum dramatically increased gentamicin activity, leading to a >/=3-log(10) CFU/ml decrease in bacterial counts when the drug concentration exceeded the MIC. Susceptibility testing in the presence of serum was predictive of in vivo activity, since gentamicin alone significantly reduced the number of surviving bacteria in the vegetations if the peak-to-MIC ratio was greater than 1. However, gentamicin selected resistant mutants in rabbits. The intrinsic activity of gentamicin should be taken into account in evaluation of combinations of gentamicin and cell wall-active agents against enterococci.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10898678      PMCID: PMC90016          DOI: 10.1128/AAC.44.8.2077-2080.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics.

Authors:  E STEERS; E L FOLTZ; B S GRAVES
Journal:  Antibiot Chemother (Northfield)       Date:  1959-05

2.  Once-daily dosing of aminoglycosides.

Authors:  J Blaser; C König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-12       Impact factor: 3.267

3.  Studies on the interaction between serum bactericidal activity and antibiotics in vitro.

Authors:  W H Traub; J C Sherris
Journal:  Chemotherapy       Date:  1970       Impact factor: 2.544

4.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

5.  A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides.

Authors:  M Z Ali; M B Goetz
Journal:  Clin Infect Dis       Date:  1997-05       Impact factor: 9.079

6.  The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

7.  Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci.

Authors:  R C Moellering; A N Weinberg
Journal:  J Clin Invest       Date:  1971-12       Impact factor: 14.808

Review 8.  Enterococci acquire new kinds of resistance.

Authors:  R Leclercq
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

9.  Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  Am J Med       Date:  1984-10       Impact factor: 4.965

Review 10.  The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.

Authors:  J M Hyatt; P S McKinnon; G S Zimmer; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

View more
  7 in total

1.  Simulation of human gentamicin pharmacokinetics in an experimental Enterococcus faecalis endocarditis model.

Authors:  Laurent Dubé; Jocelyne Caillon; Christèle Gras-Le Guen; Cédric Jacqueline; Marie-France Kergueris; Jean-Claude Granry; Gilles Potel; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

2.  Relationship between the level of acquired resistance to gentamicin and synergism with amoxicillin in Enterococcus faecalis.

Authors:  Elisabeth Aslangul; Raymond Ruimy; Françoise Chau; Louis Garry; Antoine Andremont; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  Acquired gentamicin resistance by permeability impairment in Enterococcus faecalis.

Authors:  Elisabeth Aslangul; Laurent Massias; Alain Meulemans; Françoise Chau; Antoine Andremont; Patrice Courvalin; Bruno Fantin; Raymond Ruimy
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

Review 4.  Seventy-Five Years of Research on Protein Binding.

Authors:  Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

5.  The optimal aminoglycoside and its dosage for the treatment of severe Enterococcus faecalis infection. An experimental study in the rabbit endocarditis model.

Authors:  L Dubé; J Caillon; C Jacqueline; D Bugnon; G Potel; N Asseray
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-08       Impact factor: 3.267

6.  Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an experimental foreign-body infection model.

Authors:  Ulrika Furustrand Tafin; Ivana Majic; Cyrine Zalila Belkhodja; Bertrand Betrisey; Stéphane Corvec; Werner Zimmerli; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

7.  Molecular detection and antibiotyping of multi-drug resistant Enterococcus faecium from healthy broiler chickens in Bangladesh.

Authors:  Krishna Roy; Md Saiful Islam; Anamika Paul; Samina Ievy; Mithun Talukder; Md Abdus Sobur; Fatimah Muhammad Ballah; Md Shahidur Rahman Khan; Md Tanvir Rahman
Journal:  Vet Med Sci       Date:  2021-11-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.